VolitionRX

VNRX

Medical - Devices · Healthcare

Price

$0.78

+0.01 (+1.21%)

Market Cap

$6.5M

Exchange

New York Stock Exchange Arca

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+102.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.6M (2021) → 5.3M (2025)

VolitionRx is a medical diagnostics company that develops blood tests to help detect cancer and other serious diseases. Its core technology is called "Nu.Q," which measures tiny pieces of DNA called nucleosomes that float in the bloodstream when cells die or become cancerous. The company targets hospitals, clinics, and research institutions, and its tests are designed to work on standard lab equipment already used by most healthcare providers.

VolitionRx makes money by licensing its technology and selling diagnostic test kits to labs and research partners. The company operates primarily in the United States and Europe, with research activities based in Belgium. It is a small, early-stage company that is not yet profitable, as shown by its deeply negative operating margin. The main growth driver is gaining regulatory approvals and clinical adoption for its cancer screening tests, but the key risk is that it continues to burn cash while waiting for those approvals to come through.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+299.8% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+13.7% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$10M/ year

↓ Declining (-30% vs prior year)

583.6% of revenue

32.4x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.0%ownership

Relatively low insider ownership

Cash Runway

~2 months

$3M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Revenue accelerating

VolitionRX grew revenue 300% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

74.2%

Premium pricing power — 74.2% gross margin

Operating Margin

-543.0%

Losing money on operations — -543.0%

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+88.5%

Fast-growing sales (+88.5% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-835.6%

Burning cash (-835.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial